Abstract
Antithrombotic therapy is the cornerstone of pharmacological treatment in patients undergoing primary percutaneous coronary intervention (PCI). However, the acute management of ST elevation myocardial infarction (STEMI) patients includes therapy for pain relief and potential additional strategies for cardioprotection. The safety and efficacy of some commonly used treatments have been questioned by recent evidence. Indeed a concern about morphine use is the interaction between opioids and oral P2Y(12) inhibitors; early beta-blocker treatment has shown conflicting results for the improvement of clinical outcomes; and supplemental oxygen therapy lacks benefit in patients without hypoxia and may be of potential harm. Other additional strategies remain disappointing; however, some treatments may be selectively used. Therefore, we intend to present a critical updated review of complementary pharmacotherapy for a modern treatment approach for STEMI patients undergoing primary PCI.
Original language | English |
---|---|
Pages (from-to) | 463-474 |
Number of pages | 12 |
Journal | American Journal of Cardiovascular Drugs |
Volume | 22 |
Issue number | 5 |
Early online date | 22 Mar 2022 |
DOIs | |
Publication status | Published - Sept 2022 |
Keywords
- ST-SEGMENT-ELEVATION
- PERCUTANEOUS CORONARY INTERVENTION
- ACUTE MYOCARDIAL-INFARCTION
- DOSE INTRACORONARY ADENOSINE
- REPERFUSION INJURY
- OXYGEN-THERAPY
- NO-REFLOW
- MICROVASCULAR OBSTRUCTION
- VENTRICULAR-FUNCTION
- CYCLOSPORINE-A